10-Q: BioRegenx Reports Increased Losses in Q2 2024 Amidst Product Issues and Merger Integration

BioRegenx, Inc. reports a significant increase in net losses for the second quarter of 2024, driven by decreased sales, increased returns, and higher operating expenses following a merger and product issues.

Summary

• BioRegenx, Inc. reported a net loss of $4,258,586 for the six months ended June 30, 2024, a substantial increase from the $824,299 loss in the same period of 2023.
• Net sales decreased by 34% to $1,283,580 for the six months ended June 30, 2024, compared to $1,938,862 in the same period of 2023, primarily due to product issues with the medical testing machine.
• Returns increased significantly by 444% to $258,903 for the six months ended June 30, 2024, compared to $47,576 in the same period of 2023, due to product issues and a resulting equity refund offer.
• Operating expenses increased by 138% to $4,973,269 for the six months ended June 30, 2024, compared to $2,090,926 in the same period of 2023, driven by increased selling, general, and administrative expenses, including equity compensation and professional fees.
• The company completed a merger with Findit, Inc. on March 8, 2024, and acquired DocSun Biomedical Holdings, Inc. on January 8, 2024, which impacted the financial results.
• The company has a working capital deficit of $3,093,956 as of June 30, 2024, and notes payable of $522,500 are in default, raising substantial doubt about the company's ability to continue as a going concern.
• The company issued convertible notes for $130,000 in June and July of 2024, with a 16% interest rate and the option to convert into common shares at $0.0009 per share.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to significant losses, declining sales, high returns, a working capital deficit, debt defaults, and ineffective internal controls. The company's ability to continue as a going concern is in doubt, making it a high-risk investment.

Positives

• The company acquired DocSun Biomedical Holdings, Inc. on January 8, 2024, expanding its product line with medical diagnostic technology.
• The company completed a merger with Findit, Inc. on March 8, 2024, which may provide future synergies.

Negatives

• The company experienced a significant decrease in net sales and a substantial increase in returns due to product issues with the medical testing machine.
• The company's operating expenses increased significantly, driven by higher selling, general, and administrative costs, including equity compensation and professional fees.
• The company has a substantial working capital deficit and significant debt in default, raising concerns about its ability to continue as a going concern.
• The company's internal controls over financial reporting were deemed ineffective due to material weaknesses.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses, cash flow deficits, and a working capital deficit.
• The company's dependence on raising additional debt or equity financing to continue operations poses a significant risk.
• The company's product issues with the medical testing machine have negatively impacted sales and distributor relationships.
• The company's internal control weaknesses could lead to material misstatements in financial reporting.
• The company is involved in disputes with certain parties, including former officers and board members, which could have a material adverse effect on the company's financial condition.

Future Outlook

Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital, but there is no assurance that such financing plans will be successful. The company anticipates generating losses and may be unable to continue operations in the future.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.
• Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital.
• Management has yet to find a solution to its funding requirements.

Industry Context

The company operates in the medical test equipment and nutritional products industry, which is competitive and subject to regulatory changes. The company's recent merger and acquisition activities reflect a trend of consolidation in the healthcare sector. The product issues and resulting returns highlight the importance of quality control and customer satisfaction in this industry.

Comparison to Industry Standards

• The company's significant increase in net losses and decrease in sales are worse than industry averages for companies in the medical device and nutritional supplement sectors.
• Comparable companies in the medical device sector, such as Medtronic and Abbott, typically report consistent revenue growth and profitability, unlike BioRegenx's current financial performance.
• Companies in the nutritional supplement industry, such as Herbalife and Nu Skin, generally maintain higher gross profit margins and lower return rates than BioRegenx.
• The company's high operating expenses, particularly in selling, general, and administrative costs, are significantly higher than industry benchmarks for companies of similar size and revenue.
• The company's working capital deficit and debt default are indicative of severe financial distress, which is not typical for established companies in these sectors.

Legal Proceedings

• The company is involved in disputes with certain parties, including former officers and board members and vendors associated with their activities.

Related Party Transactions

• The company rents its home office from BBD Holdings, LLC, which is controlled by an officer and director.
• The company sells a product subject to a royalty agreement with the VHS Pool, in which a related party has a creditor interest.
• The company has a worldwide distribution agreement with GlycoCheck B.V., where directors of BioRegenx may have an ownership interest.
• The company's legal counselors included a member of the board of directors.
• The company reimburses certain officers for company expenses paid through individual accounts.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential for dilution from future capital raises.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers may experience disruptions in product availability or service due to the company's financial challenges.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to raise additional debt or equity financing to fund ongoing operations.
• The company will continue to address the material weaknesses in its internal control over financial reporting.
• The company will continue to work through disputes with certain parties.

Key Dates

Keywords

BioRegenx, financial results, net loss, sales decrease, product issues, merger, acquisition, operating expenses, working capital, going concern, convertible notes, internal controls, debt default